As of 2025-09-15, the EV/EBITDA ratio of Trillium Therapeutics Inc (TRIL.TO) is -43.33. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TRIL.TO's latest enterprise value is 2,478.11 mil CAD. TRIL.TO's TTM EBITDA according to its financial statements is -57.19 mil CAD. Dividing these 2 quantities gives us the above TRIL.TO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.6x - 23.0x | 15.8x |
| Forward P/E multiples | 8.6x - 23.0x | 15.8x |
| Fair Price | (4.93) - (15.12) | (10.03) |
| Upside | -121.1% - -164.8% | -143.0% |
| Date | EV/EBITDA |